Fig. 4.

Unadjusted response rates and comparative adjusted odds ratios for durability of effectiveness outcomes for ixekizumab versus other individual biologics. Outcomes include a durability of effectiveness outcome, whereby patients achieve at least Psoriasis Area and Severity Index (PASI)90 and/or Static Physician Global Assessment (sPGA) score of 0 or 1 at week 12 and subsequently achieve either or both of the following outcomes at months 6 and 12: at least PASI75 or achieving an improvement in sPGA of 2 or more points from baseline; b PASI100 durability outcome, whereby patients achieve a PASI100 score at week 12 and subsequently at both months 6 and 12; c PASI90 durability outcome, whereby patients achieve a PASI90 score at week 12 and subsequently at both months 6 and 12. For unadjusted and adjusted response rates, patients with missing outcomes were imputed as non-responder imputation (NRI). Adjusted analyses were performed using frequentist model averaging (FMA). Results are statistically significant if 95% confidence intervals (CIs) of the odds ratios do not cross 1. For instances that lower CI shows 1.0, *denotes that the result is significant as lower CI is greater than 1. In c the lower CI for ixekizumab (IXE) vs. secukinumab (SEC) odds ratio is 1.013. ADA adalimumab, BROD brodalumab, CI confidence interval, FMA frequentist model averaging, GUS guselkumab, n number of patients who achieved the outcome, N total number of patients in treatment group, NRI non-responder imputation, RIS risankizumab, TILD tildrakizumab, UST ustekinumab